Number of days with grade 2 or higher bleeding by age group, overall, and within disease treatment category
| Outcome . | P for interaction between age group and disease treatment category . | 0-5 y . | 6-12 y . | 13-18 y . | ≥ 19 y . | Total . | P for overall comparison of the 4 age groups . | Significant pairwise comparisons* . |
|---|---|---|---|---|---|---|---|---|
| No. of patients | 66 | 69 | 65 | 1072 | 1272 | |||
| No. of days with bleeding of grade 2 or higher, all patients, median (quartile 1, quartile 3) | < .001 | 3 (1, 6.5) | 3 (1, 6) | 3 (0, 9.5) | 1 (0, 4) | 1 (0, 4) | < .001 | C, E, F |
| Unknown, n | 6 | 13 | 13 | 115 | 147 | |||
| No. of days with bleeding of grade 2 or higher, within disease treatment category | ||||||||
| Autologous or syngeneic stem cell transplantation, median (quartile 1, quartile 3) | 4 (2, 7) | 2 (1, 8) | 2 (1, 8) | 0 (0, 1) | 1 (0, 2) | < .001 | C, E, F | |
| Unknown, n | 3 | 1 | 2 | 31 | 37 | |||
| Allogeneic stem cell transplantation, median (quartile 1, quartile 3) | 3 (1, 6.5) | 3.5 (1.5, 6) | 5 (2, 17) | 2 (0, 5) | 2 (1, 6) | .002 | E, F | |
| Unknown, n | 3 | 5 | 8 | 47 | 63 | |||
| Chemotherapy without HSCT for hematologic malignancy, median (quartile 1, quartile 3) | 1 (0, 3) | 1 (0, 1) | 0 (0, 3) | 2 (0, 4) | 2 (0, 4) | .30 | ||
| Unknown, n | 0 | 6 | 2 | 37 | 45 | |||
| Chemotherapy without HSCT for solid tumor, median (quartile 1, quartile 3) | 2 (0, 3) | 0 (0, 0) | 0 (0, 2) | .20 | ||||
| Unknown, n | 0 | 1 | 1 | 0 | 2 |
| Outcome . | P for interaction between age group and disease treatment category . | 0-5 y . | 6-12 y . | 13-18 y . | ≥ 19 y . | Total . | P for overall comparison of the 4 age groups . | Significant pairwise comparisons* . |
|---|---|---|---|---|---|---|---|---|
| No. of patients | 66 | 69 | 65 | 1072 | 1272 | |||
| No. of days with bleeding of grade 2 or higher, all patients, median (quartile 1, quartile 3) | < .001 | 3 (1, 6.5) | 3 (1, 6) | 3 (0, 9.5) | 1 (0, 4) | 1 (0, 4) | < .001 | C, E, F |
| Unknown, n | 6 | 13 | 13 | 115 | 147 | |||
| No. of days with bleeding of grade 2 or higher, within disease treatment category | ||||||||
| Autologous or syngeneic stem cell transplantation, median (quartile 1, quartile 3) | 4 (2, 7) | 2 (1, 8) | 2 (1, 8) | 0 (0, 1) | 1 (0, 2) | < .001 | C, E, F | |
| Unknown, n | 3 | 1 | 2 | 31 | 37 | |||
| Allogeneic stem cell transplantation, median (quartile 1, quartile 3) | 3 (1, 6.5) | 3.5 (1.5, 6) | 5 (2, 17) | 2 (0, 5) | 2 (1, 6) | .002 | E, F | |
| Unknown, n | 3 | 5 | 8 | 47 | 63 | |||
| Chemotherapy without HSCT for hematologic malignancy, median (quartile 1, quartile 3) | 1 (0, 3) | 1 (0, 1) | 0 (0, 3) | 2 (0, 4) | 2 (0, 4) | .30 | ||
| Unknown, n | 0 | 6 | 2 | 37 | 45 | |||
| Chemotherapy without HSCT for solid tumor, median (quartile 1, quartile 3) | 2 (0, 3) | 0 (0, 0) | 0 (0, 2) | .20 | ||||
| Unknown, n | 0 | 1 | 1 | 0 | 2 |
A: 0-5 years vs 6-12 years; B: 0-5 years vs 13-18 years; C: 0-5 years vs ≥ 19 years; D: 6-12 years vs 13-18 years; E: 6-12 years vs ≥ 19 years; F: 13-18 years vs ≥ 19 years.